To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have marginal zone lymphoma that has continued to grow or has come back despite prior therapy that included a drug targeting the CD20 protein (such as rituximab).
- At least 3 weeks must have passed between completion of previous therapy and entry into the study (70 days for radio-immunotherapies).
- Patients must be able to be walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Ariela Noy at 212-639-7423.